290 related articles for article (PubMed ID: 21792878)
1. SH2-domain mutations in STAT3 in hyper-IgE syndrome patients result in impairment of IL-10 function.
Giacomelli M; Tamassia N; Moratto D; Bertolini P; Ricci G; Bertulli C; Plebani A; Cassatella M; Bazzoni F; Badolato R
Eur J Immunol; 2011 Oct; 41(10):3075-84. PubMed ID: 21792878
[TBL] [Abstract][Full Text] [Related]
2. Defects along the T(H)17 differentiation pathway underlie genetically distinct forms of the hyper IgE syndrome.
Al Khatib S; Keles S; Garcia-Lloret M; Karakoc-Aydiner E; Reisli I; Artac H; Camcioglu Y; Cokugras H; Somer A; Kutukculer N; Yilmaz M; Ikinciogullari A; Yegin O; Yüksek M; Genel F; Kucukosmanoglu E; Baki A; Bahceciler NN; Rambhatla A; Nickerson DW; McGhee S; Barlan IB; Chatila T
J Allergy Clin Immunol; 2009 Aug; 124(2):342-8, 348.e1-5. PubMed ID: 19577286
[TBL] [Abstract][Full Text] [Related]
3. STAT3-Mediated Transcriptional Regulation of Osteopontin in STAT3 Loss-of-Function Related Hyper IgE Syndrome.
Goel S; Sahu S; Minz RW; Singh S; Suri D; Oh YM; Rawat A; Sehgal S; Saikia B
Front Immunol; 2018; 9():1080. PubMed ID: 29868029
[TBL] [Abstract][Full Text] [Related]
4. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome.
Renner ED; Rylaarsdam S; Anover-Sombke S; Rack AL; Reichenbach J; Carey JC; Zhu Q; Jansson AF; Barboza J; Schimke LF; Leppert MF; Getz MM; Seger RA; Hill HR; Belohradsky BH; Torgerson TR; Ochs HD
J Allergy Clin Immunol; 2008 Jul; 122(1):181-7. PubMed ID: 18602572
[TBL] [Abstract][Full Text] [Related]
5. Quantitative defects in invariant NKT cells and TLR responses in patients with hyper-IgE syndrome.
Gutierrez-Hincapié S; Muskus-López CE; Montoya CJ; Trujillo-Vargas CM
Allergol Immunopathol (Madr); 2015; 43(6):553-61. PubMed ID: 25796310
[TBL] [Abstract][Full Text] [Related]
6. Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells.
Saito M; Nagasawa M; Takada H; Hara T; Tsuchiya S; Agematsu K; Yamada M; Kawamura N; Ariga T; Tsuge I; Nonoyama S; Karasuyama H; Minegishi Y
J Exp Med; 2011 Feb; 208(2):235-49. PubMed ID: 21300911
[TBL] [Abstract][Full Text] [Related]
7. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome.
Minegishi Y; Saito M; Tsuchiya S; Tsuge I; Takada H; Hara T; Kawamura N; Ariga T; Pasic S; Stojkovic O; Metin A; Karasuyama H
Nature; 2007 Aug; 448(7157):1058-62. PubMed ID: 17676033
[TBL] [Abstract][Full Text] [Related]
8. Eosinophilia and reduced STAT3 signaling affect neutrophil cell death in autosomal-dominant Hyper-IgE syndrome.
Farmand S; Kremer B; Häffner M; Pütsep K; Bergman P; Sundin M; Ritterbusch H; Seidl M; Follo M; Henneke P; Henriques-Normark B
Eur J Immunol; 2018 Dec; 48(12):1975-1988. PubMed ID: 30315710
[TBL] [Abstract][Full Text] [Related]
9. IL-21 enhances SOCS gene expression and inhibits LPS-induced cytokine production in human monocyte-derived dendritic cells.
Strengell M; Lehtonen A; Matikainen S; Julkunen I
J Leukoc Biol; 2006 Jun; 79(6):1279-85. PubMed ID: 16551679
[TBL] [Abstract][Full Text] [Related]
10. STAT3 mutations correlated with hyper-IgE syndrome lead to blockage of IL-6/STAT3 signalling pathway.
He J; Shi J; Xu X; Zhang W; Wang Y; Chen X; Du Y; Zhu N; Zhang J; Wang Q; Yang J
J Biosci; 2012 Jun; 37(2):243-57. PubMed ID: 22581330
[TBL] [Abstract][Full Text] [Related]
11. Suppressor of cytokine signalling-3 at pathological levels does not regulate lipopolysaccharide or interleukin-10 control of tumour necrosis factor-alpha production by human monocytes.
Prêle CM; Keith-Magee AL; Yerkovich ST; Murcha M; Hart PH
Immunology; 2006 Sep; 119(1):8-17. PubMed ID: 16925527
[TBL] [Abstract][Full Text] [Related]
12. Diminished allergic disease in patients with STAT3 mutations reveals a role for STAT3 signaling in mast cell degranulation.
Siegel AM; Stone KD; Cruse G; Lawrence MG; Olivera A; Jung MY; Barber JS; Freeman AF; Holland SM; O'Brien M; Jones N; Nelson CG; Wisch LB; Kong HH; Desai A; Farber O; Gilfillan AM; Rivera J; Milner JD
J Allergy Clin Immunol; 2013 Dec; 132(6):1388-96. PubMed ID: 24184145
[TBL] [Abstract][Full Text] [Related]
13. The Potential and Limits of Hematopoietic Stem Cell Transplantation for the Treatment of Autosomal Dominant Hyper-IgE Syndrome.
Yanagimachi M; Ohya T; Yokosuka T; Kajiwara R; Tanaka F; Goto H; Takashima T; Morio T; Yokota S
J Clin Immunol; 2016 Jul; 36(5):511-6. PubMed ID: 27091139
[TBL] [Abstract][Full Text] [Related]
14. Clinical Manifestations and Genetic Analysis of 17 Patients with Autosomal Dominant Hyper-IgE Syndrome in Mainland China: New Reports and a Literature Review.
Wu J; Chen J; Tian ZQ; Zhang H; Gong RL; Chen TX; Hong L
J Clin Immunol; 2017 Feb; 37(2):166-179. PubMed ID: 28197791
[TBL] [Abstract][Full Text] [Related]
15. STAT3 mutations in the hyper-IgE syndrome.
Holland SM; DeLeo FR; Elloumi HZ; Hsu AP; Uzel G; Brodsky N; Freeman AF; Demidowich A; Davis J; Turner ML; Anderson VL; Darnell DN; Welch PA; Kuhns DB; Frucht DM; Malech HL; Gallin JI; Kobayashi SD; Whitney AR; Voyich JM; Musser JM; Woellner C; Schäffer AA; Puck JM; Grimbacher B
N Engl J Med; 2007 Oct; 357(16):1608-19. PubMed ID: 17881745
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Role of
Moffitt K; Cheung E; Manis J; Malley R
Infect Immun; 2018 May; 86(5):. PubMed ID: 29463618
[TBL] [Abstract][Full Text] [Related]
17. Successful haploidentical donor hematopoietic stem cell transplant and restoration of STAT3 function in an adolescent with autosomal dominant hyper-IgE syndrome.
Patel NC; Gallagher JL; Torgerson TR; Gilman AL
J Clin Immunol; 2015 Jul; 35(5):479-85. PubMed ID: 25962528
[TBL] [Abstract][Full Text] [Related]
18. Clinical Profile of Hyper-IgE Syndrome in India.
Saikia B; Rawat A; Minz RW; Suri D; Pandiarajan V; Jindal A; Sahu S; Karim A; Desai M; Taur PD; Pandrowala A; Gowri V; Madkaikar M; Dalvi A; Yadav RM; Lashkari HP; Raj R; Uppuluri R; Swaminathan VV; Bhattad S; Cyril G; Kumar H; Shukla A; Kalra M; Govindaraj G; Singh S
Front Immunol; 2021; 12():626593. PubMed ID: 33717144
[No Abstract] [Full Text] [Related]
19. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages.
Williams L; Bradley L; Smith A; Foxwell B
J Immunol; 2004 Jan; 172(1):567-76. PubMed ID: 14688368
[TBL] [Abstract][Full Text] [Related]
20. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome.
Milner JD; Brenchley JM; Laurence A; Freeman AF; Hill BJ; Elias KM; Kanno Y; Spalding C; Elloumi HZ; Paulson ML; Davis J; Hsu A; Asher AI; O'Shea J; Holland SM; Paul WE; Douek DC
Nature; 2008 Apr; 452(7188):773-6. PubMed ID: 18337720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
